Aktienanalyse zu Arcus Biosciences Inc (RCUS)RCUSArcus Biosciences Inc

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcus Biosciences Inc (RCUS) is a good buy right now due to its current price of $29.21, which is significantly below the average analyst price target of $39.00 (from Goldman Sachs and Wedbush). The company has shown a remarkable 1-year change of +170.21%, indicating strong growth potential. Additionally, insider buying has increased by 186.42% over the last quarter, suggesting confidence in the company's future. However, the main risk is the negative earnings per share (EPS) of -0.72 reported in the last quarter, which reflects ongoing financial challenges.

3 analysts cover RCUS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 27.44.